Medicinal Chemistry Research Program (Project-003)

药物化学研究计划（Project-003）

• 批准号: 9369068
• 负责人: DEBORAH W KNAPP
• 金额: $ 2.84万
• 依托单位: PURDUE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9369068
• 关键词: Antineoplastic Agents; Award; Basic Science; Cancer Center Support Grant; Canis familiaris; Cells; Chemicals; Clinic; Collaborations; Development; Discipline; Drug Delivery Systems; Evaluation; Extramural Activities; Faculty; Faculty Recruitment; Funding; Grant; Human; In Vitro; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Methods; Modeling; Molecular; NCI Center for Cancer Research; Paper; Peer Review; Pharmaceutical Chemistry; Phase; Phase III Clinical Trials; Program Research Project Grants; Publications; Recruitment Activity; Research; Research Personnel; Signal Transduction; Structure; Technology; Therapeutic Agents; Translations; Universities; anti-cancer therapeutic; base; college; comparative; drug discovery; faculty mentor; in vivo; in vivo Model; inter-institutional; meetings; member; novel; oncology; preclinical development; programs; protein protein interaction; screening; structural biology; therapeutic development; tool

Medicinal Chemistry Research Program: Project Summary The Medicinal Chemistry Program (MC) in the Purdue University Center for Cancer Research (PCCR) drives the drug discovery effort of the Center by serving as the central component for basic research in cancer drug discovery and drug discovery methods. The Program consists of 23 members who integrate their expertise in novel synthetic strategies and advanced technologies with the other Research Programs in the Center, to advance translation of promising entities to the clinic. During the past four years, nine new cancer- focused faculty members were recruited to the MC Program. MC members are united by a focus on cancer drug discovery, and represent diverse disciplines that are drawn from seven academic departments and four colleges from across the Purdue campus. The MC Program has a strong publication record, producing 286 papers between 2010 and 2013 with 2% involving intra-programmatic collaborations, 19% representing inter- programmatic and 21% engaging inter-institutional partners; overall, 39% MC publications were a result of collaborative efforts with other cancer researchers. Combined, the MC membership has a current portfolio of over $1.7 million of total direct peer-reviewed, extramural support, with 44% of awards being cancer-focused grants funded by the NCI, NSF, ACS or DOD. The MC Program is structured around two Research Clusters. Research Cluster 1, Synthetic Medicinal Chemistry, and the cornerstone of the MC Program, reflects the strengths of the Center in medicinal chemistry. A distinguished group of senior and junior faculty develops and utilizes target-based medicinal chemistry approaches to drug discovery. The efforts of this group have led to the development of 13 agents that have been in Phase 0, Phase I, Phase II, or Phase III clinical trials in the last funding cycle. Ten other agents have progressed to preclinical development (in vivo studies). Research Cluster 2, Target Discovery and Translation, encompasses a focus on target discovery, in vitro and in cell molecular evaluation of potential anti-cancer therapeutic agents, and the development and use of in vivo models and methods for the analysis of potential anti-cancer drugs. Tools have been developed for high- throughput single cell screening as well as in cell sensing and identifying protein-protein interaction networks. There is a specific emphasis on comparative oncology including studies of dogs with naturally-occurring cancers that closely mimic the human condition. The canine models are being evaluated for their impact on the translation of therapeutic agents to humans. Over the past four years, many MC projects have spawned highly productive inter-programmatic collaborations involving members of the Cell Identity and Signaling (CIS), Chemical and Structural Biology (CSB), and Drug Delivery and Molecular Sensing (DDMS) Programs. The Program Leader and Co-Leader's efforts in cancer-focused faculty recruiting and mentoring, and organizing Program meetings and the PCCR-based Bladder Cancer Discovery Group, have enhanced the two Research Clusters and overall research progress of the MC Program.

药物化学研究计划： 项目概要 普渡大学癌症研究中心 (PCCR) 药物化学项目 (MC) 作为癌症基础研究的核心组成部分，推动该中心的药物发现工作 药物发现和药物发现方法。该计划由 23 名成员组成，他们将各自的 与其他研究项目在新颖的合成策略和先进技术方面的专业知识 中心，将有前景的实体推进临床转化。在过去的四年里，有九种新的癌症—— 重点教师被招募到 MC 项目。 MC 成员因对癌症的关注而团结在一起 药物发现，并代表来自七个学术部门和四个 普渡大学校园各处的大学。 MC 计划拥有强大的出版记录，共产生 286 2010 年至 2013 年间发表的论文，其中 2% 涉及项目内合作，19% 涉及项目间合作 计划性的和 21% 参与的机构间合作伙伴；总体而言，39% 的 MC 出版物是由于 与其他癌症研究人员的合作努力。 MC 会员当前的组合包括 直接同行评审的外部支持总额超过 170 万美元，其中 44% 的奖项专注于癌症 由 NCI、NSF、ACS 或 DOD 资助的赠款。 MC 项目围绕两个研究集群构建。 研究集群 1，合成药物化学，是 MC 项目的基石，反映了 药物化学中心的优势。培养并培养了一支由高级和初级教师组成的杰出团队 利用基于目标的药物化学方法进行药物发现。该小组的努力导致 13种药物的开发已进入0期、I期、II期或III期临床试验 最后一个融资周期。其他十种药物已进入临床前开发（体内研究）。研究 集群 2，目标发现和翻译，重点关注体外和细胞内的目标发现 潜在抗癌治疗药物的分子评价以及体内开发和使用 分析潜在抗癌药物的模型和方法。工具已开发用于高 高通量单细胞筛选以及细胞传感和识别蛋白质-蛋白质相互作用网络。 特别强调比较肿瘤学，包括对狗自然发生的肿瘤的研究 与人类状况非常相似的癌症。正在评估犬类模型对人类的影响 将治疗剂转化为人类。四年来，众多MC项目催生了高度 涉及细胞识别和信号传导 (CIS) 成员的富有成效的项目间合作， 化学和结构生物学 (CSB) 以及药物输送和分子传感 (DDMS) 项目。这 项目负责人和联合负责人在以癌症为重点的教师招募、指导和组织方面所做的努力 计划会议和基于 PCCR 的膀胱癌发现小组增强了这两项研究 MC计划集群及整体研究进展。